ATE365563T1 - Verfahren zur schrittweise bindung von polyethylenglykol (peg) an polypeptide - Google Patents

Verfahren zur schrittweise bindung von polyethylenglykol (peg) an polypeptide

Info

Publication number
ATE365563T1
ATE365563T1 AT04003053T AT04003053T ATE365563T1 AT E365563 T1 ATE365563 T1 AT E365563T1 AT 04003053 T AT04003053 T AT 04003053T AT 04003053 T AT04003053 T AT 04003053T AT E365563 T1 ATE365563 T1 AT E365563T1
Authority
AT
Austria
Prior art keywords
steply
polypeptides
peg
polyethylene glycol
binding polyethylene
Prior art date
Application number
AT04003053T
Other languages
English (en)
Inventor
Tayar Nabil El
Michael J Roberts
Milton Harris
Wayne Sawlivich
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE365563T1 publication Critical patent/ATE365563T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04003053T 1998-04-28 1999-04-28 Verfahren zur schrittweise bindung von polyethylenglykol (peg) an polypeptide ATE365563T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28

Publications (1)

Publication Number Publication Date
ATE365563T1 true ATE365563T1 (de) 2007-07-15

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99920094T ATE275422T1 (de) 1998-04-28 1999-04-28 Konjugate aus polyole und beta-interferon
AT04003053T ATE365563T1 (de) 1998-04-28 1999-04-28 Verfahren zur schrittweise bindung von polyethylenglykol (peg) an polypeptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99920094T ATE275422T1 (de) 1998-04-28 1999-04-28 Konjugate aus polyole und beta-interferon

Country Status (30)

Country Link
US (3) US6638500B1 (de)
EP (2) EP1075281B1 (de)
JP (2) JP4574007B2 (de)
KR (1) KR100622796B1 (de)
CN (2) CN1187094C (de)
AR (1) AR020070A1 (de)
AT (2) ATE275422T1 (de)
AU (1) AU762621B2 (de)
BG (2) BG65046B1 (de)
BR (1) BR9910023A (de)
CA (2) CA2330451A1 (de)
CY (1) CY1108022T1 (de)
CZ (2) CZ298597B6 (de)
DE (2) DE69936409T2 (de)
DK (2) DK1075281T3 (de)
EA (2) EA003789B1 (de)
EE (1) EE05214B1 (de)
ES (2) ES2285286T3 (de)
HU (1) HUP0300548A3 (de)
IL (1) IL139286A (de)
NO (2) NO329749B1 (de)
NZ (1) NZ507456A (de)
PL (2) PL193352B1 (de)
PT (2) PT1421956E (de)
SI (2) SI1421956T1 (de)
SK (2) SK286654B6 (de)
TR (2) TR200101751T2 (de)
TW (2) TWI232882B (de)
UA (2) UA66857C2 (de)
WO (1) WO1999055377A2 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
EE05111B1 (et) * 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
HU229888B1 (en) * 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
CN100512879C (zh) * 1999-04-23 2009-07-15 阿尔萨公司 用于脂质体中的有可裂解键的缀合物
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
TR200101086A3 (de) * 1999-10-15 2001-08-21
AU2223401A (en) 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Branched polyalkylene glycols
SK11672002A3 (sk) 2000-01-10 2002-12-03 Maxygen Holdings Ltd. Polypeptidový konjugát, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
DE60236796D1 (de) 2001-01-30 2010-08-05 Kyowa Hakko Kirin Co Ltd Verzweigte polyalkylenglykole
EP1234583A1 (de) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
DK1476181T3 (en) 2002-01-18 2016-05-23 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USE THEREOF
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050502A (sr) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP1586334A1 (de) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF Konjugate mit PEG
ZA200609412B (en) 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
BRPI0510527A (pt) 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
EP1750751B1 (de) 2004-06-01 2013-04-10 Ares Trading S.A. Stabilisierte flüssige interferon-formulierungen
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
DE602005025805D1 (de) 2004-12-21 2011-02-17 Nektar Therapeutics San Carlos Stabilisierte polymer-thiol-reagenzien
WO2006071840A2 (en) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
EP2284191A3 (de) 2004-12-22 2011-07-20 Ambrx, Inc. Prozess zur Herstellung von hGH
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
WO2007019331A2 (en) * 2005-08-04 2007-02-15 Nektar Therapeutics Al, Corporation Conjugates of a g-csf moiety and a polymer
SG155183A1 (en) 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
WO2007025991A2 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
WO2007130453A2 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
EP2076533B1 (de) 2007-05-02 2014-10-08 Ambrx, Inc. Modifizierte interferon-beta-polypeptide und ihre verwendungen
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
ES2387236T3 (es) 2007-12-20 2012-09-18 Merck Serono S.A. Formulaciones de interferón beta pegilado
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
WO2011101242A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
EP3372617B1 (de) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsproteinarzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
US20130183280A1 (en) 2010-07-15 2013-07-18 Novo Nordisk A/S Stabilized factor viii variants
AU2011303916A1 (en) 2010-09-15 2013-03-21 Novo Nordisk A/S Factor VIII variants having a decreased cellular uptake
US9913880B2 (en) 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
KR101979045B1 (ko) * 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US20150030564A1 (en) 2012-02-29 2015-01-29 Toray Industries, Inc. Inhibitory agent for body cavity fluid accumulation
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
EP3782652A1 (de) 2014-08-19 2021-02-24 Biogen MA Inc. Pegylierungsverfahren
KR20170141692A (ko) 2015-05-01 2017-12-26 알리스타 파마슈티컬즈, 인크. 안구 장애를 치료하기 위한 아디포넥틴 펩티드모방체
CN107949575B (zh) * 2015-06-19 2022-03-08 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN115920016A (zh) 2015-11-09 2023-04-07 科罗拉多州立大学董事会法人团体 用于治疗高胱氨酸尿症的组合物和方法
AU2018254410B2 (en) * 2017-04-17 2025-02-06 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
CN111356460A (zh) 2017-11-24 2020-06-30 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
CN113382775A (zh) 2019-01-28 2021-09-10 东丽株式会社 肝细胞生长因子或其活性片段的聚乙二醇修饰物
WO2020158691A1 (ja) 2019-01-28 2020-08-06 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5766581A (en) * 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
WO1995031479A1 (en) * 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
IL133974A0 (en) * 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
UA66857C2 (uk) 2004-06-15
ATE275422T1 (de) 2004-09-15
ES2224649T3 (es) 2005-03-01
JP2010184929A (ja) 2010-08-26
EP1421956B1 (de) 2007-06-27
NO20100324L (no) 2000-12-28
US7700314B2 (en) 2010-04-20
NO332224B1 (no) 2012-07-30
CZ20003995A3 (en) 2001-06-13
JP2002512983A (ja) 2002-05-08
HK1038194A1 (en) 2002-03-08
US20070141620A1 (en) 2007-06-21
CN1302209A (zh) 2001-07-04
DK1421956T3 (da) 2007-10-01
TWI232882B (en) 2005-05-21
UA79430C2 (en) 2007-06-25
PL193352B1 (pl) 2007-02-28
ES2285286T3 (es) 2007-11-16
WO1999055377A9 (en) 2000-03-02
EA200300382A1 (ru) 2005-02-24
DE69936409D1 (de) 2007-08-09
DE69920002T2 (de) 2005-09-22
WO1999055377A3 (en) 1999-12-29
CZ298579B6 (cs) 2007-11-14
EP1075281A2 (de) 2001-02-14
CN1187094C (zh) 2005-02-02
SK16222000A3 (sk) 2001-04-09
IL139286A (en) 2005-12-18
SK286217B6 (sk) 2008-05-06
EP1421956A1 (de) 2004-05-26
AR020070A1 (es) 2002-04-10
BG64694B1 (bg) 2005-12-30
IL139286A0 (en) 2001-11-25
CN100335503C (zh) 2007-09-05
TR200003161T2 (tr) 2001-01-22
HUP0300548A3 (en) 2005-07-28
SK286654B6 (sk) 2009-03-05
EA003789B1 (ru) 2003-10-30
BR9910023A (pt) 2000-12-26
JP4574007B2 (ja) 2010-11-04
US6638500B1 (en) 2003-10-28
DE69920002D1 (de) 2004-10-14
EE05214B1 (et) 2009-10-15
EP1075281B1 (de) 2004-09-08
CY1108022T1 (el) 2013-09-04
HUP0300548A2 (hu) 2003-06-28
DE69936409T2 (de) 2008-04-17
BG104871A (en) 2001-07-31
EE200000614A (et) 2002-04-15
TWI266800B (en) 2006-11-21
TR200101751T2 (tr) 2002-05-21
PT1075281E (pt) 2004-11-30
SI1421956T1 (sl) 2007-10-31
CA2565375A1 (en) 1999-11-04
HK1076115A1 (en) 2006-01-06
SI1075281T1 (en) 2005-02-28
PL344490A1 (en) 2001-11-05
AU762621B2 (en) 2003-07-03
CZ298597B6 (cs) 2007-11-21
EA200001111A1 (ru) 2001-04-23
NO329749B1 (no) 2010-12-13
AU3767499A (en) 1999-11-16
WO1999055377A2 (en) 1999-11-04
DK1075281T3 (da) 2005-01-03
KR100622796B1 (ko) 2006-09-13
KR20010071158A (ko) 2001-07-28
BG109291A (en) 2006-04-28
PL196533B1 (pl) 2008-01-31
BG65046B1 (bg) 2007-01-31
PT1421956E (pt) 2007-07-13
NZ507456A (en) 2003-10-31
NO20005337L (no) 2000-12-28
EA005495B1 (ru) 2005-02-24
CA2330451A1 (en) 1999-11-04
CN1637020A (zh) 2005-07-13
US7357925B2 (en) 2008-04-15
US20040043002A1 (en) 2004-03-04
NO20005337D0 (no) 2000-10-23

Similar Documents

Publication Publication Date Title
ATE365563T1 (de) Verfahren zur schrittweise bindung von polyethylenglykol (peg) an polypeptide
EP1009855A4 (de) Verfahren zur zelltrennung
DE69826705D1 (de) Verfahren zur dermalen verabreichung von polypeptiden
DE60027099D1 (de) Verfahren zur Rundfunkausstrahlung von Informationen
DE69804274D1 (de) Verfahren zur Verstärkung von Konstruktionselementen
DE69812693D1 (de) Verfahren zur oligomerisierung von isobuten
DE50010474D1 (de) Verfahren zur verkapselung von bauelementen
DE69817839D1 (de) Verfahren zur erhöhung der photosynthese
DE69731276D1 (de) Verfahren zur angabe der grösse von minizellen
ATE294139T1 (de) Verfahren zur reinigung von lithiumcarbonat
DE69816208D1 (de) Verfahren zur entfernung von schwefel
DE69715424D1 (de) Verfahren zur halogenierung von isoolefin-para-alkylstyrol-copolymeren
ATE220558T1 (de) Verbessertes verfahren zur stabilisierung von proteinen
DE69719722D1 (de) Verfahren zur identifizierung von beweglichen objekten
DE59811160D1 (de) Verfahren zur pfropfung von lignin
DE69811943D1 (de) Verfahren zur markierung von kontaktlinsenverpackungen
DE59806510D1 (de) Verfahren zur Kennzeichnung von Gehäusen
DE59812413D1 (de) Verfahren zur trägerfreien ablenkungselektrophorese
DE69835345D1 (de) Verfahren zur kodierung von mehrwortinformation
DE69705478D1 (de) Verfahren zur Identifizierung von Fahrbahnmarkierungen
DE59806044D1 (de) Verfahren zur ermittlung von segmentzeiten
DE69830556D1 (de) Verfahren zur Bestimmung von glykosylierten Proteinen
DE69836075D1 (de) Verfahren zur spaltung von fusionproteinen
DE69709695D1 (de) Verfahren zur seitenzusammensetzung
DE59706714D1 (de) Verfahren zur kodierung von sendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1421956

Country of ref document: EP

EEFA Change of the company name